Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 combined with AK117 in advanced malignant tumors and recurrent/metastatic head and neck squamous cell carcinoma
CTR20220121Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- May 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, ligufalimab in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), epithelial ovarian cancer (EOC), Cervical Cancer (CC), sponsored by Akeso, Inc.. Started May 2022; status: active.
02
Drugs
ivonescimabligufalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)epithelial ovarian cancer (EOC)Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20220121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220121.